UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 524

Sortiert nach

Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes

Journal of endocrinological investigation, 2024-03

2024

Volltextzugriff (PDF)

Antineoplastic drug occupational exposure: a new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive Buccal Micronucleus Cytome Assay biomarker

Toxicology letters, 2019-11, Vol.316, p.20-26

2019

Volltextzugriff (PDF)

Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations

European journal of cancer (1990), 2017-02, Vol.72, p.S167-S167

2017

Volltextzugriff (PDF)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)

HemaSphere, 2022-06, Vol.6 (Suppl), p.994-995

2022

Volltextzugriff (PDF)

Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e273-e273

2015

Volltextzugriff (PDF)

Will people change their vector-control practices in the presence of an imperfect dengue vaccine?

Epidemiology and infection, 2014-03, Vol.142 (3), p.625-633

2014

Volltextzugriff (PDF)

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

Annals of oncology, 2023-10, Vol.34, p.S623-S624

2023

Volltextzugriff (PDF)

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

The New England journal of medicine, 2008-07, Vol.359 (1), p.31-42

2008

Volltextzugriff (PDF)

1813 - Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations

European journal of cancer (1990), 2017-02, Vol.72, p.S167-S167

2017

Volltextzugriff (PDF)

195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors

Immuno-oncology technology, 2022-12, Vol.16, p.100307, Article 100307

2022

Volltextzugriff (PDF)

PRO3 SUCCESSOR STUDY: TREATMENT AND HEALTH CARE RESOURCE UTILIZATION BY SICKLE CELL PATIENTS WHO PARTICIPATED IN THE SUSTAIN STUDY IN THE UNITED STATES

Value in health, 2019-05, Vol.22, p.S335-S335

2019

Volltextzugriff (PDF)

A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.9133-9133

2007

Volltextzugriff (PDF)

Relationship Between Initial Parenteral Iron Therapy Dosing and Treatment Effectiveness: A Real-World Retrospective Analysis

Journal of blood medicine, 2022-03, Vol.13, p.133-142

2022

Volltextzugriff (PDF)

Tecniche di aiuto alla decisione per la valutazione d'impatto ambientale: un'analisi comparata su di un caso di studio

Ce.S.E.T. Aestimum, 2009-06 (24)

R. Boccia

2009

Volltextzugriff (PDF)

6016 POSTER A novel organic arsenic S-dimethylarsino-glutathione (ZIO-101) experience in hematological malignancies

European journal of cancer supplements, 2007, Vol.5 (4), p.349-350

2007

Volltextzugriff (PDF)

PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)

HemaSphere, 2019-06, Vol.3 (S1), p.319-n/a

2019

Volltextzugriff (PDF)

PF703 LONG‐TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM

HemaSphere, 2019-06, Vol.3 (S1), p.306-n/a

2019

Volltextzugriff (PDF)

5PSQ-117 Failure mode and effects criticality analysis: multicentric application on cancer chemotherapy process

European journal of hospital pharmacy. Science and practice, 2018-03, Vol.25 (Suppl 1), p.A218-A219

2018

Volltextzugriff (PDF)

Temperature- and volume-dependent dissolution of amifostine 500 mg reconstituted for subcutaneous injection in normal saline or sterile water for injection

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3207-3207

2005

Volltextzugriff (PDF)

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Annals of oncology, 2019-10, Vol.30 (10), p.1613

2019

Volltextzugriff (PDF)

A phase I/II study of oral melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e18574-e18574

2011

Volltextzugriff (PDF)

S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW‐UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES

HemaSphere, 2019-06, Vol.3 (S1), p.380-381

2019

Volltextzugriff (PDF)

A preliminary report of a phase II trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.18156-18156

2007

Volltextzugriff (PDF)

Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.8070-8070

2011

Volltextzugriff (PDF)

A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8134-8134

2010

Volltextzugriff (PDF)

1 – 25 von 524

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(364)
Mit Volltextzugriff
(356)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(282)
Life Sciences & Biomedicine
(138)
Technology
(137)
Humans
(128)
Engineering
(125)
Engineering, Electrical & Electronic
(124)
Male
(80)
Female
(76)
Biological And Medical Sciences
(51)
Middle Aged
(51)
Adult
(48)
Medical Sciences
(38)
Microwave Antennas
(38)
Aged
(31)
Antennas
(30)
Risk Factors
(27)
Microwave Measurement
(26)
Public Health
(26)
Animals
(25)
Infectious Diseases
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes

Antineoplastic drug occupational exposure: a new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive Buccal Micronucleus Cytome Assay biomarker

Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)

Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study

Will people change their vector-control practices in the presence of an imperfect dengue vaccine?

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

1813 - Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations

195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors

PRO3 SUCCESSOR STUDY: TREATMENT AND HEALTH CARE RESOURCE UTILIZATION BY SICKLE CELL PATIENTS WHO PARTICIPATED IN THE SUSTAIN STUDY IN THE UNITED STATES

A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia

Relationship Between Initial Parenteral Iron Therapy Dosing and Treatment Effectiveness: A Real-World Retrospective Analysis

Tecniche di aiuto alla decisione per la valutazione d'impatto ambientale: un'analisi comparata su di un caso di studio

6016 POSTER A novel organic arsenic S-dimethylarsino-glutathione (ZIO-101) experience in hematological malignancies

PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)

PF703 LONG‐TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM

5PSQ-117 Failure mode and effects criticality analysis: multicentric application on cancer chemotherapy process

Temperature- and volume-dependent dissolution of amifostine 500 mg reconstituted for subcutaneous injection in normal saline or sterile water for injection

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

A phase I/II study of oral melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM)

S853 SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW‐UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES

A preliminary report of a phase II trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer

Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial

A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM)

Aktive Filter

Suchergebnisse filtern